CD93 and neoplasm: Zhang and colleagues found that an increased expression of CD93 was associated with a poor prognosis in cancer patients and was correlated with mismatch repair (MMR) gene expression, tumor mutation burden (TMB), microsatellite instability (MSI) and immune cell infiltration.